<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017433</url>
  </required_header>
  <id_info>
    <org_study_id>CTI-1057</org_study_id>
    <secondary_id>CDR0000068688</secondary_id>
    <nct_id>NCT00017433</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients&#xD;
      who have relapsed or refractory stage II or stage III multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate of patients with relapsed or refractory stage II&#xD;
      or III multiple myeloma treated with arsenic trioxide. II. Determine the overall and&#xD;
      relapse-free survival rates of patients treated with this drug. III. Determine the safety&#xD;
      profile of this drug in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive arsenic trioxide IV on days 1-5 and 8-12. Treatment repeats every 4&#xD;
      weeks for up to 6 courses. Patients are followed at 4 weeks after the last treatment dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">January 2001</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of multiple myeloma Stage II or III (Durie-Salmon)&#xD;
        Relapsed or refractory to conventional therapy No monoclonal gammopathy or indolent or&#xD;
        smoldering myeloma Measurable disease by serum and urine M protein and/or plasmacytoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 70-100% Life&#xD;
        expectancy: 3 months Hematopoietic: Granulocyte count greater than 1,200/mm3 Platelet count&#xD;
        greater than 100,000/mm3 Hemoglobin greater than 10 g/dL Hepatic: Bilirubin less than 2&#xD;
        times upper limit of normal (ULN) SGOT/SGPT less than 2 times ULN Renal: Creatinine no&#xD;
        greater than 2.5 mg/dL Cardiovascular: Absolute QT interval less than 460 msec in the&#xD;
        presence of normal potassium and magnesium levels&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 28 days since prior biologic therapy&#xD;
        Chemotherapy: No more than 3 prior chemotherapy regimens, including no more than 2&#xD;
        cytotoxic regimens AND 1 high-dose cytotoxic regimen as part of stem cell transplantation&#xD;
        Endocrine therapy: At least 28 days since prior endocrine therapy Radiotherapy: At least 28&#xD;
        days since prior radiotherapy (except for focal radiotherapy for symptom control) Surgery:&#xD;
        Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Paradise, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CTI BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialist</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2004</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

